Effects of herpes simplex virus type 2 glycoprotein vaccines and CLDC adjuvant on genital herpes infection in the guinea pig

详细信息    查看全文

• 作者：David I. Bernstein^a ; ^{David.Bernstein@cchmc.org} ; Julie D. Earwood^a ; Fernando J. Bravo^a ; Gary H. Cohen^b ; Roselyn J. Eisenberg^c ; Jennifer R. Clark^a ; Jeffrey Fairman^d ; Rhonda D. Cardin^a
• 关键词：Herpes simplex ; HSV vaccine ; HSV glycoproteins ; Guinea pig ; Genital herpes ; CLDC adjuvant
• 刊名：Vaccine
• 出版年：2011
• 出版时间：3 March 2011
• 年：2011
• 卷：29
• 期：11
• 页码：2071-2078
• 全文大小：633 K

文摘

Genital herpes simplex virus (HSV) infections are common but results from vaccine trials with HSV-2 glycoprotein D (gD) have been disappointing. We therefore compared a similar HSV gD2 vaccine, to a further truncated gD2 vaccine, to a vaccine with gD2 plus gB2 and gH2/gL2 and to a vaccine with only gB2 and gH2/gL2 in a guinea pig model of genital herpes. All vaccines were administered with cationic liposome-DNA complexes (CLDC) as an adjuvant. All vaccines significantly decreased the severity of acute genital disease and vaginal virus replication compared to the placebo group. The majority of animals in all groups developed at least one episode of recurrent disease but the frequency of recurrent disease was significantly reduced by each vaccine compared to placebo. No vaccine was significantly more protective than gD2 alone for any of the parameters described above. No vaccine decreased recurrent virus shedding. When protection against acute infection of dorsal root ganglia and the spinal cord was evaluated all vaccines decreased the per cent of animal with detectable virus and the quantity of virus but again no vaccine was significantly more protective than another. Improvements in HSV-2 vaccines may require inclusion of more T cell targets, more potent adjuvants or live virus vaccines.